OncoMatch/Clinical Trials/NCT07870265
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
Is NCT07870265 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for unresectable metastatic melanoma.
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable metastatic melanoma after disease relapse. The method will be based on a CRISPR/Cas12a system combined with isothermal amplification and endpoint electrochemical detection using electrode chips and low-cost instrumentation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07870265 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages